DWA
IMMU

Dorsey Wright & Associates’s Immunomedics Inc IMMU Stock Holding History

Dorsey Wright & Associates’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,785
Closed -$37K – 368
2018
Q3 		$37K Buy
+1,785
New +$42.3K 0.01% 127

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Dorsey Wright & Associates's IMMU Position: Q4 2018 in Review

Dorsey Wright & Associates sold out of Immunomedics Inc (IMMU) in Q4 2018, closing a stake of 1,785 shares — an estimated $37K sold.

Dorsey Wright & Associates first reported a position in IMMU in Q3 2018 and held it in 1 quarter. The position peaked at $37K in Q3 2018. 205 funds tracked by Wall St. Rank hold IMMU as of Q4 2018.

  • Dorsey Wright & Associates reported no remaining Immunomedics Inc position as of Q4 2018 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1,785 Immunomedics Inc shares in Q4 2018, an estimated $37K.
  • Dorsey Wright & Associates first reported a position in Immunomedics Inc in Q3 2018 and held it in 1 quarter.
  • Dorsey Wright & Associates's Immunomedics Inc position peaked at $37K in Q3 2018.
  • 205 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2018.

Based on Dorsey Wright & Associates's 13F filing for Q4 2018, filed 7 Jan 2019.